LMWH to Prevent Preeclampsia and Fetal Growth Restriction

• Status: Terminated
• Trial end date: 2003-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Florence
• Treatments: Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

• Previous severe preeclampsia

• Previous severe fetal growth restriction

• Heterozygous Factor V Leiden

• Heterozygous G20210A prothrombin gene mutations

Exclusion Criteria:

• renal disease

• chronic hypertension

• preexisting diabetes mellitus

• homozygosity for Factor V Leiden

• homozygosity for prothrombin G20210A mutation

• hyperhomocysteinemia

• protein C deficency

• protein S deficency

• antithrombin deficiency

• positive anticardiolipin antibodies

• positive lupus anticoagulant